Clinical validity of Metroticket calculator in transplant patients undergoing prior chemoembolization for hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyung-Don | - |
dc.contributor.author | Song, Gi-Won | - |
dc.contributor.author | Shim, Ju Hyun | - |
dc.contributor.author | Han, Seungbong | - |
dc.contributor.author | An, Jihyun | - |
dc.contributor.author | Moon, Deok-Bog | - |
dc.contributor.author | Kim, Kang Mo | - |
dc.contributor.author | Lim, Young-Suk | - |
dc.contributor.author | Ko, Gi-Young | - |
dc.contributor.author | Hwang, Shin | - |
dc.contributor.author | Lee, Han Chu | - |
dc.contributor.author | Yu, Eunsil | - |
dc.contributor.author | Sung, Kyu-Bo | - |
dc.contributor.author | Lee, Sung-Gyu | - |
dc.date.available | 2020-02-27T19:43:15Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2017-03 | - |
dc.identifier.issn | 1936-0533 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/6381 | - |
dc.description.abstract | To test the predictive performance of the Metroticket calculator for survival after liver transplantation (LT) of patients with hepatocellular carcinoma (HCC) undergoing prior transarterial chemoembolization (TACE). A total of 142 patients treated with TACE and subsequent LT who had arterial enhancing HCC(s) were entered into this analysis. Tumor parameters measured by the enhancement radiological method pre-LT or by pathology post-LT were incorporated into the Metroticket analysis. The calculator was validated in terms of calibration and discrimination capacity. Mean 3- and 5-year survival rates predicted in the radiological model for all 142 patients were 76.4 and 70.1 %, respectively, lying comfortably within the 95 % confidence interval (CI) of the observed survival rate estimates (72.8-86.2 and 68.6-83.2 %, respectively). In the pathological model incorporating microvascular invasion, the mean anticipated survival rate at 5 years of 120 patients with viable nodules on explants was 69.5 %, also lying inside the 95 % CI of the actuarial rates (67.9-83.5 %). The c-indices as measures of discriminatory power were 0.61 and 0.62, respectively, for the 3- and 5-year predictions in the radiological model, and 0.72 for the 5-year prediction in the pathological model. The corresponding findings were similar for subgroups with hepatitis B virus infection and undergoing living-donor LT. The Metroticket calculation based on explant data accurately predicts post-LT survival of HCC patients with prior TACE. Imaging estimate-based predictions before LT appear to provide poorer discrimination than calibration. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.relation.isPartOf | HEPATOLOGY INTERNATIONAL | - |
dc.subject | DONOR LIVER-TRANSPLANTATION | - |
dc.subject | TRANSARTERIAL CHEMOEMBOLIZATION | - |
dc.subject | MILAN CRITERIA | - |
dc.subject | SINGLE-CENTER | - |
dc.subject | WAITING-LIST | - |
dc.subject | RECURRENCE | - |
dc.subject | PREDICTION | - |
dc.subject | SURVIVAL | - |
dc.subject | THERAPY | - |
dc.subject | MODELS | - |
dc.title | Clinical validity of Metroticket calculator in transplant patients undergoing prior chemoembolization for hepatocellular carcinoma | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000398773600010 | - |
dc.identifier.doi | 10.1007/s12072-017-9785-2 | - |
dc.identifier.bibliographicCitation | HEPATOLOGY INTERNATIONAL, v.11, no.2, pp.209 - 219 | - |
dc.identifier.scopusid | 2-s2.0-85011256341 | - |
dc.citation.endPage | 219 | - |
dc.citation.startPage | 209 | - |
dc.citation.title | HEPATOLOGY INTERNATIONAL | - |
dc.citation.volume | 11 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | Han, Seungbong | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Metroticket calculator | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | Transarterial chemoembolization | - |
dc.subject.keywordAuthor | Liver transplantation | - |
dc.subject.keywordAuthor | Validation | - |
dc.subject.keywordPlus | DONOR LIVER-TRANSPLANTATION | - |
dc.subject.keywordPlus | TRANSARTERIAL CHEMOEMBOLIZATION | - |
dc.subject.keywordPlus | MILAN CRITERIA | - |
dc.subject.keywordPlus | SINGLE-CENTER | - |
dc.subject.keywordPlus | WAITING-LIST | - |
dc.subject.keywordPlus | RECURRENCE | - |
dc.subject.keywordPlus | PREDICTION | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | MODELS | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.